Minerva Neurosciences (NERV) Return on Capital Employed (2014 - 2026)

Minerva Neurosciences has reported Return on Capital Employed for 13 years, with the latest figure at 30.46% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 2729.0% year-over-year to 30.46%; the trailing twelve-month figure through Mar 2026 stood at 30.46% (up 2729.0% YoY), and the FY2025 full-year result was 23.14%, up 2631.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 30.46%, down from 24.86% in the prior quarter.
• The five-year high for Return on Capital Employed was 24.86% in Q4 2025, with the low at 69.04% in Q3 2022.
• Historically, Return on Capital Employed has averaged 50.15% across 5 years, with a median of 55.09% in 2025.
• Annual changes were most pronounced in 2022 — Return on Capital Employed sank 7304 bps — and 2023, when it surged 3503 bps.
• Minerva Neurosciences' Return on Capital Employed stood at 45.02% in 2022, then gained by 9 bps to 40.79% in 2023, then slumped by 44 bps to 58.83% in 2024, then soared by 58 bps to 24.86% in 2025, then slipped by 22 bps to 30.46% in 2026.
• The last three Return on Capital Employed figures came in at 30.46% (Q1 2026), 24.86% (Q4 2025), and 55.09% (Q3 2025), per Business Quant data.